1. South Korea Stocks

  2. •

    Industrials

  3. •

    Industrial - Machinery
GemVax&KAEL Co.,Ltd

GemVax&KAEL Co.,Ltd

082270.KQ
GemVax&KAEL Co.,LtdKR flagKOSDAQ
10,870.00
KRW
-460.00
- -
477.79BMarket Cap
GemVax&KAEL Co.,Ltd
082270.KQ
(KOSDAQ)

Recent

price

10,870.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
861.47
2,135.01
1,313.1
2,648.81
2,729.46
2,662.89
949.17
3,883.67
1,438.37
1,186.46
1,686.76
1,449.19
1,829.95
1,835.99
1,582.77
1,977.74
2,055.19
Revenue per Share
-753.19
-377.99
-372
50
-864.27
-87
-700
-1,002
-326
-2,636
42
289.45
-473.24
-691
-2,202
-275
-92.74
Basic EPS, GAAP
-511.99
7.06
-560.37
-1,055.76
226.64
-343.55
-1,249.06
-358.53
-32.55
-70.26
25.44
-311.68
-332.8
-141.13
-809.47
-24.41
-72.62
Free Cash Flow per Basic Share
- -
23.48
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-258.96
-662.08
-1,095.03
-989.26
-1,528.79
-2,060.14
-2,607.31
-7,221.98
-2,984.28
-5,447.21
-1,015.62
-642.05
-1,108.54
-1,883.72
-4,125.83
-1,384.7
-1,359.32
Book Value per Share
1,958.98
1,574.96
907.29
1,180.04
277.38
2,289.22
2,728.73
4,737.66
3,418.21
2,507.37
3,348
3,519.58
3,045.28
2,619.4
649.54
1,306.85
1,819.43
Tangible Book Value per Share
21
24
24
25
37
28
30
12
33
36
39
42
41
39
40
41
43
Basic Weighted Avg Shares
18,006
52,118
31,763
66,530
101,051
75,074
28,403
47,875
47,240
42,664
65,663
60,371
75,804
72,209
62,692
81,531
87,415
Sales/Revenue/Turnover
-43.13
-16.29
-14.68
-15.89
-5.5
-3.68
-21.26
-7.25
2.95
-16.94
2.19
-4.06
-4.71
-10.9
-101.51
4.37
6.57
Operating Margin (%)
934
1,805
2,832
4,424
4,299
4,935
6,631
2,910
1,843
1,681
1,718
2,315
3,039
3,991
4,338
4,309
4,233
Depreciation Expense
-15,743
-9,227
-8,998
1,256
-31,997
-2,453
-20,947
-12,352
-10,707
-94,787
1,635
12,058
-19,604
-27,177
-87,219
-11,337
-3,945
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-87.43
-17.7
-28.33
1.89
-31.66
-3.27
-73.75
-25.8
-22.66
-222.17
2.49
19.97
-25.86
-37.64
-139.12
-13.9
-4.51
Profit Margin (%)
-4,414
4,377
-15,661
-5,974
-13,145
-19,157
-28,154
-17,395
49,089
46,929
47,828
36,472
44,312
7,742
-45,104
-22,522
8,224
Working Capital
- -
11,050
11,041
4,042
15,639
9,047
2,789
- -
- -
1,365
1,215
817
514
495
22,663
10,162
22,409
LT Debt
47,353
73,878
61,286
66,567
43,935
99,177
100,390
66,114
113,810
92,268
135,206
153,986
134,351
108,019
29,006
57,229
80,730
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.15
-1.61
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-2.71
-49.37
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
54,145
47,909
35,660
LT Borrowings
10,000
10,000
22,267
LT Finance Leases
189
162
142
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
42
44
44
Market Capitalization
2,097,200
1,206,722
1,444,018

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
35,778
42,915
55,075
Cash, Cash Equivalents & STI
19,718
22,778
28,655
Accounts Receivable, Net
4,974
4,760
9,041
Inventories
8,416
8,675
10,394
Total Current Liabilities
70,798
65,437
46,851
Payables & Accruals
- -
- -
- -
ST Debt
54,145
47,909
35,660
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.25%
1.14%
97.3%
Free Cash Flow
-96.5%
-216.79%
-96.86%
Net Income, GAAP
193.07%
109.49%
-87%
Sales/Revenue/Turnover
7.89%
5.93%
30.05%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
14,731
16,952
12,735
18,273
62,692
2025
12,373
25,017
17,978
26,164
81,531
2026
18,257
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-877
56
-206
- -
-2,202
2025
-223
-36.68
-60.22
- -
-275
2026
-35
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Haina Intelligent Equipment International Holdings Limited (1645.HK)
Top High Image Corp. (3284.TWO)
Dürr Aktiengesellschaft (DUERF)
Nantong Guosheng Intelligence Technology Group Co., Ltd. (688558.SS)
Inepar S.A. Indústria e Construções (INEP4.SA)
Xometry, Inc. (XMTR)
Business
GemVax&KAEL Co., Ltd. engages primarily in the manufacturing and sale of coating resins and chemical air filters used in semiconductor and display production, specializing in environmental pollution control equipment such as CA filters and gas scrubber resins designed to prevent contamination and eliminate harmful gases within semiconductor and display manufacturing processes. The company also operates a biopharmaceutical division focused on the research and development of peptide-based new drugs, including anti-cancer vaccines and therapeutics for neurodegenerative diseases, notably developing GV1001, a peptide drug candidate targeting progressive supranuclear palsy (PSP) and Alzheimer's disease. Founded in 1998 and headquartered in Daejeon, South Korea, GemVax&KAEL organizes its business into environmental pollution control, IT, and bio-business segments, serving primarily the semiconductor, display, and pharmaceutical markets. Recently, GemVax&KAEL has advanced its biopharmaceutical pipeline with promising clinical progress; in October 2024, it announced topline results from a Phase 2a clinical trial of GV1001 for PSP, indicating potential for Phase 3 advancement and positioning GV1001 as a prospective first treatment for this condition. The company has also received FDA Fast Track designation for GV1001 in PSP treatment and secured orphan medicinal product designation in Europe, complementing prior approvals in the United States and South Korea. Additionally, GemVax&KAEL is conducting a global Phase 2 Alzheimer's disease clinical trial and is preparing for a global PSP clinical trial while continuing research on anti-cancer immunotherapeutics. On the environmental control front, the company maintains leadership in chemical filters and pollution control systems for semiconductor and display manufacturing, sustaining steady sales growth in this segment. GemVax&KAEL operates primarily in South Korea with a global outlook for its biopharmaceutical products, targeting neurodegenerative diseases and cancer markets worldwide. Its integrated approach combines high-value environmental technology solutions for the semiconductor industry with cutting-edge clinical-stage pharmaceuticals. The company leverages its expertise and long-standing foundation in environmental contaminant control since its establishment in 1998 to pioneer innovative drug development in neurodegenerative therapy.